Can CorMedix's Melinta Acquisition Aid Growth Beyond DefenCath? [Yahoo! Finance]
CorMedix Inc. (CRMD)
NASDAQ:AMEX Investor Relations:
cormedix.com
Company Research
Source: Yahoo! Finance
acquiring Melinta Therapeutics for $300 million in August 2025. The deal added seven approved products to CRMD's portfolio, while diversifying its commercial portfolio and expanding its footprint in hospital acute care and infectious disease markets. These acquired products from Melinta contributed $12.8 million to CRMD's top line during the third quarter of 2025, which, up until now, was tied almost entirely to product sales from DefenCath. DefenCath was approved by the FDA in late 2023 as the first and only antimicrobial catheter lock solution available in the United States. The product was launched in 2024 in both the hospital inpatient and outpatient hemodialysis settings. In the first nine months of 2025, DefenCath recorded $167.6 million in net sales. The Melinta acquisition expanded CorMedix's revenue base and created near-term growth opportunities, led by Rezzayo, which is approved for treating candidemia and invasive candidiasis in adults. Rezzayo is also in late-stage
Show less
Read more
Impact Snapshot
Event Time:
CRMD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CRMD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CRMD alerts
High impacting CorMedix Inc. news events
Weekly update
A roundup of the hottest topics
CRMD
News
- CorMedix (CRMD): Assessing Valuation After a Strong Multi-Year Share Price Run [Yahoo! Finance]Yahoo! Finance
- Is It Too Late to Consider CorMedix After DefenCath Progress and Strong Price Gains? [Yahoo! Finance]Yahoo! Finance
- CorMedix (NASDAQ:CRMD) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $14.00 price target on the stock.MarketBeat
- CorMedix Therapeutics Announces Positive Data From Ongoing Real World Evidence Study of DefenCathGlobeNewswire
- 5 High Earnings Yield Value Picks Ahead of Key Economic Reports [Yahoo! Finance]Yahoo! Finance
CRMD
Earnings
- 11/12/25 - Beat
CRMD
Sec Filings
- 12/19/25 - Form 4
- 12/18/25 - Form 144
- 12/11/25 - Form 4
- CRMD's page on the SEC website